Add BrightSurf on Google Email

Science News for June 14, 2014


Will diabetes patients benefit from the Affordable Care Act?

The Affordable Care Act (ACA) offers significant benefits for diabetes patients, including non-exclusion of pre-existing conditions and access to preventive services. The law also authorizes the creation of the National Diabetes Prevention Program, delivering evidence-based lifestyle change programs to prevent type 2 diabetes.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalDiabetes Technology & Therapeutics·DateJun 14, 2014

New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo

A post-hoc analysis of patients with type 2 diabetes found that intensification of insulin therapy with Januvia (sitagliptin) 100 mg once-daily resulted in lower incidence of nighttime hypoglycemia compared to placebo. This is a positive finding for treatment approaches aimed at lowering nocturnal hypoglycemia.

Late-breaking observational data show patients with type 2 diabetes taking JANUVIA (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin

A retrospective cohort study found patients taking JANUVIA and metformin initiated insulin therapy at a slower rate than those taking a sulfonylurea and metformin. The study suggests that real-world data may provide insight into the effects of different oral treatment regimens on the initiation of insulin use.